Early trial tests new drug combo for tough head & neck cancers
Disease control
Terminated
This early-stage study aimed to find a safe dose for combining a new immunotherapy drug (pembrolizumab) with standard chemotherapy and radiation in patients with advanced head and neck cancer. The main goal was to check if the combination caused acceptable side effects, especiall…
Phase: PHASE1 • Sponsor: Royal Marsden NHS Foundation Trust • Aim: Disease control
Last updated Apr 09, 2026 19:34 UTC